GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
PARIS--(BUSINESS WIRE)--Dec 14, 2021--
France General United States United Kingdom Magali Taiel Gensight Biologics Euronext Gensight Biologics
Source: nwitimes.com